Use of hydrochloride salt of the compound of general formula (I) for the manufacture of orally administered medicament for prophylaxis of breast cancer in postmenopausal women during sufficient period of time and in effective dose whereby the dose being from 55 to 65 mg per day preferably 60 mg per day.

In the present invention there is disclosed the use of raloxifene or a pharmaceutically acceptable salt or solvate thereof in the preparation of an orally administered medicament for preventing breast cancer in a post-menopausal female said medicament to be administered to said post-menopausal female for a sufficient term and at an effective dose wherein said effective dose is between about 55 mg to about 65 mg/day.

This invention comprises raloxifene hydrochloride a surfactant being sorbitan fatty acid ester or a polyoxyethylene sorbitan fatty acid ester polyvinylpyrrolidone and a water soluble diluent which is polyol or sugar.

A pharmaceutical unit dosage form is provided comprising from 50 to 200 mg of a benzothiophene preferably raloxifene or a pharmaceutically-acceptable salt thereof.

The invention relates to the utilization of the general formula (I) and the pharmaceutically acceptable salts thereof for preparing an oral medicine administered in a dose ranging from 55 to 65 mg/ per day for preventing and reducing the probability of exposure or development of estrogen-dependent breast carcinoma in postmenopausal women.